Pharmadrug Inc. (CSE:PHRX)
Canada flag Canada · Delayed Price · Currency is CAD
0.0150
0.00 (0.00%)
May 1, 2026, 9:30 AM EST

Pharmadrug Balance Sheet

Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
0.020.080.410.010.96
Short-Term Investments
--0.010.320.34
Cash & Short-Term Investments
0.020.080.420.331.3
Cash Growth
-76.15%-82.26%28.49%-74.58%-70.59%
Accounts Receivable
----0.02
Other Receivables
0.010.020.020.020.06
Receivables
0.010.020.0210.08
Inventory
----0.16
Prepaid Expenses
-0.010.010.010.01
Restricted Cash
0.010.040.15--
Other Current Assets
----0.05
Total Current Assets
0.040.150.61.341.59
Property, Plant & Equipment
----0.1
Goodwill
---6.2410.47
Other Intangible Assets
0.510.560.64.537.35
Total Assets
0.550.711.212.1119.52
Accounts Payable
0.40.370.450.530.25
Accrued Expenses
-0.240.450.250.19
Current Portion of Long-Term Debt
1.521.351.771.42-
Current Portion of Leases
----0.04
Total Current Liabilities
1.911.962.662.20.48
Long-Term Debt
----0.79
Long-Term Leases
----0.04
Long-Term Deferred Tax Liabilities
---1.011.25
Other Long-Term Liabilities
0.29--0.070.1
Total Liabilities
2.21.962.663.282.66
Common Stock
34.0133.9933.2131.2230.61
Retained Earnings
-39.49-39.11-38.3-25.12-19.4
Comprehensive Income & Other
3.713.713.382.745.66
Total Common Equity
-1.76-1.4-1.78.8416.87
Minority Interest
0.110.160.24--
Shareholders' Equity
-1.65-1.24-1.478.8416.87
Total Liabilities & Equity
0.550.711.212.1119.52
Total Debt
1.521.351.771.420.87
Net Cash (Debt)
-1.5-1.27-1.34-1.090.43
Net Cash Growth
-----86.91%
Net Cash Per Share
-0.01-0.01-0.02-0.020.01
Filing Date Shares Outstanding
108.24108.2104.6950.849.48
Total Common Shares Outstanding
108.24107.7388.1750.848.69
Working Capital
-1.88-1.81-2.07-0.861.11
Book Value Per Share
-0.02-0.01-0.020.170.35
Tangible Book Value
-2.28-1.97-2.31-1.94-0.96
Tangible Book Value Per Share
-0.02-0.02-0.03-0.04-0.02
Machinery
----0.05
Source: S&P Global Market Intelligence. Standard template. Financial Sources.